LT5414B - Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu - Google Patents
Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu Download PDFInfo
- Publication number
- LT5414B LT5414B LT2005043A LT2005043A LT5414B LT 5414 B LT5414 B LT 5414B LT 2005043 A LT2005043 A LT 2005043A LT 2005043 A LT2005043 A LT 2005043A LT 5414 B LT5414 B LT 5414B
- Authority
- LT
- Lithuania
- Prior art keywords
- protein
- hybridoma
- hybridomas
- monoclonal antibodies
- particles
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 96
- 239000012634 fragment Substances 0.000 title claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000002245 particle Substances 0.000 title claims abstract description 17
- 230000002163 immunogen Effects 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 8
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 30
- 241000150452 Orthohantavirus Species 0.000 claims description 29
- 230000003053 immunization Effects 0.000 claims description 29
- 238000002649 immunization Methods 0.000 claims description 29
- 150000001413 amino acids Chemical group 0.000 claims description 22
- 241000699670 Mus sp. Species 0.000 claims description 21
- 238000009396 hybridization Methods 0.000 claims description 12
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 210000004989 spleen cell Anatomy 0.000 claims description 8
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 24
- 102000037865 fusion proteins Human genes 0.000 abstract description 12
- 108020001507 fusion proteins Proteins 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 28
- 101710197658 Capsid protein VP1 Proteins 0.000 description 26
- 101710132601 Capsid protein Proteins 0.000 description 25
- 101710108545 Viral protein 1 Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010063954 Mucins Proteins 0.000 description 6
- 102000015728 Mucins Human genes 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101100385565 Arabidopsis thaliana CTF7 gene Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150010030 ECO1 gene Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 241000829333 Mesocricetus auratus polyomavirus 1 Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100022492 Mucin-7 Human genes 0.000 description 1
- 101710134550 Mucin-7 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 108700010901 hantavirus proteins Proteins 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2005043A LT5414B (lt) | 2005-04-13 | 2005-04-13 | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
| PCT/EP2006/003420 WO2006108658A2 (fr) | 2005-04-13 | 2006-04-13 | Procede de production d'anticorps monoclonaux |
| US11/871,215 US7919314B2 (en) | 2005-04-13 | 2007-10-12 | Process for the production of monoclonal antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2005043A LT5414B (lt) | 2005-04-13 | 2005-04-13 | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2005043A LT2005043A (en) | 2006-10-25 |
| LT5414B true LT5414B (lt) | 2007-04-25 |
Family
ID=37026585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2005043A LT5414B (lt) | 2005-04-13 | 2005-04-13 | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US7919314B2 (fr) |
| LT (1) | LT5414B (fr) |
| WO (1) | WO2006108658A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512711B2 (en) | 2006-10-04 | 2013-08-20 | The University Of Queensland | VLP based vaccine delivery system |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030923A2 (fr) | 1997-11-13 | 2000-08-30 | Max-Delbrück-Centrum Für Molekulare Medizin | Procede d'obtention de particules semblables a des virus a base de virus de polyome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| EP0330661B1 (fr) | 1986-11-01 | 1994-01-12 | British Bio-Technology Limited | Proteines et particules de fusion |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| JPH08504091A (ja) | 1992-09-22 | 1996-05-07 | メディカル・リサーチ・カウンシル | 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| ATE314095T1 (de) * | 1998-10-21 | 2006-01-15 | Us Health | Virusähnliche partikel zur induktion von autoantikörpern |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| US20060003315A1 (en) * | 2002-06-12 | 2006-01-05 | Gavish-Galilee Bio Applications Ltd. | Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopes |
| WO2006045849A1 (fr) * | 2004-10-29 | 2006-05-04 | Cytos Biotechnology Ag | Reseaux d'antigenes de la t-cadherine et utilisations |
-
2005
- 2005-04-13 LT LT2005043A patent/LT5414B/lt not_active IP Right Cessation
-
2006
- 2006-04-13 WO PCT/EP2006/003420 patent/WO2006108658A2/fr not_active Application Discontinuation
-
2007
- 2007-10-12 US US11/871,215 patent/US7919314B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030923A2 (fr) | 1997-11-13 | 2000-08-30 | Max-Delbrück-Centrum Für Molekulare Medizin | Procede d'obtention de particules semblables a des virus a base de virus de polyome |
Non-Patent Citations (2)
| Title |
|---|
| GEDVILAITE A. ET AL.: "Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein.", VIROLIOGY, 2000, pages 21 - 35, XP004435974, DOI: doi:10.1006/viro.2000.0392 |
| SHIN CY ET AL.: "Production and characterization of monoclonal antibodies against human airway mucins.", HYBRIDOMA, 1999, pages 457 - 463, XP009073311 |
Also Published As
| Publication number | Publication date |
|---|---|
| LT2005043A (en) | 2006-10-25 |
| US20090269371A1 (en) | 2009-10-29 |
| WO2006108658A2 (fr) | 2006-10-19 |
| US7919314B2 (en) | 2011-04-05 |
| WO2006108658A3 (fr) | 2009-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1930346B1 (fr) | Anticorps obtenu en se servant d'une autruche et son procédé de production | |
| TWI445547B (zh) | 登革熱病毒胜肽疫苗及其製備與使用方法 | |
| FI105452B (fi) | Idiotyyppirokotuksen valmistus B-solulymfoomaa vastaan | |
| RU2744274C1 (ru) | Моноклональное антитело к RBD фрагменту в составе S белка вируса SARS-CoV-2 | |
| CN87105716A (zh) | 利用不溶性免疫复合物提高抗体的生产 | |
| CN102316898A (zh) | 抗cd147抗体、方法和用途 | |
| SK1152003A3 (en) | Dual specificity antibodies and methods of making and using | |
| WO2022027702A1 (fr) | Nanovaccin multimère de protéine s du nouveau coronavirus à base de ferritine d'helicobacter pylori | |
| CN104072613A (zh) | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 | |
| JP5187883B2 (ja) | 抗原ペプチドおよびその利用 | |
| CN106573985A (zh) | 抗vasa抗体及其生产方法和用途 | |
| JPH08501925A (ja) | 糖蛋白ｐに対するモノクローナル抗体 | |
| LT5414B (lt) | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu | |
| WO2014139425A1 (fr) | Anticorps monoclonal anti-blys et composition pharmaceutique contenant l'anticorps | |
| KR101495019B1 (ko) | 광견병 바이러스를 중화시킬 수 있는 결합 분자 | |
| WO2022105872A1 (fr) | Anticorps anti-tigit ou fragment de liaison à l'antigène de celui-ci | |
| US20230348902A1 (en) | Methods and compositions for making antibody libraries and antibodies isolated from the same | |
| CN109651509A (zh) | 抗cd20的人源化单抗及其制剂 | |
| CN1142505A (zh) | 诱导对表皮生长因子受体的免疫应答的抗独特型抗体 | |
| WO2015165368A1 (fr) | Anticorps monoclonal anti-her2 à action de neutralisation, et utilisation de celui-ci | |
| KR102090160B1 (ko) | 특정 항원 정제 방법 및 이를 이용한 단일클론 항체 제조 방법 | |
| WO1990001066A1 (fr) | Anticorps porcins monoclonaux et polyclonaux | |
| TWI276686B (en) | Hybridoma cell line producing monoclonal antibodies against foot-and-mouth disease virus and the monoclonal antibodies therefrom | |
| WO2023046057A1 (fr) | Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation | |
| CN111349157B (zh) | 钙粘附蛋白6的单克隆抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20140413 |